Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- A new capsule-sponge test combined with biomarkers successfully stratified 910 Barrett esophagus patients into risk groups, with high-risk patients showing 37.7% positive predictive value for dysplasia or cancer. - Patients with both atypia and aberrant p53 biomarkers demonstrated the highest risk of high-grade dysplasia or cancer, with a relative risk of 135.8 compared to low-risk patients. - The low-risk group showed only 0.4% prevalence of high-grade dysplasia or cancer, with 97.8% negative predictive value, potentially reducing unnecessary endoscopic surveillance. - The test can be administered by nurses with minimal training and does not require endoscopy resources, offering a more accessible screening approach for Barrett esophagus patients.
- The BRAID trial found that contrast-enhanced mammography and abbreviated MRI could detect up to 3,500 additional breast cancers annually in women with dense breasts. - Women with dense breast tissue, comprising 10% of those aged 50-70, face up to four times higher breast cancer risk but current screening guidelines don't account for breast density. - Additional imaging detected 85 cancers among over 9,000 women with dense breasts who had previously received negative mammogram results. - Researchers estimate these enhanced screening protocols could save approximately 700 lives per year by enabling earlier diagnosis and treatment.
